Glenmark Life Science Share Price

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.As of 25 May 2026, Glenmark Life Science share price is ₹1,049.70. The stock opened at ₹1,039.50, compared to its previous close of ₹1,039.00. During today's trading session, Glenmark Life Science share price moved in the range of ₹1,031.80 to ₹1,066.90, with an average price of ₹1,049.35 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,031.80 and a high of ₹1,066.90. On the performance front, Glenmark Life Science share price has increased by 18.64% over the last six months and is down 6.03% on a year-on-year basis.

The market capitalization of Glenmark Life Science is ₹12,715 Crs, with a P/E ratio of 22.5 and a dividend yield of 0.48%.